<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666376</url>
  </required_header>
  <id_info>
    <org_study_id>15/20/DD-BVMD</org_study_id>
    <nct_id>NCT04666376</nct_id>
  </id_info>
  <brief_title>Assessing the Technique of Ovarian Tissue Cryopreservation by Vitrification in Vietnam</brief_title>
  <official_title>Vitrified Ovarian Tissue in Cancer Patients: Assessing the Technique in Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mỹ Đức Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mỹ Đức Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian tissue cryopreservation (OTC) is a new approach on fertility preservation for young&#xD;
      female patients with cancer. It is now used by many IVF centers in the world. However, this&#xD;
      is the first study which OTC by vitrification is carried on and assessed the effectiveness of&#xD;
      the technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovaries from all less than 45 year-old breast cancer patients who undergo oophorectomy by&#xD;
      laparoscopy after treated with chemotherapy will be enrolled to the study. Pieces of cortex&#xD;
      of each patient will divide into two groups. Group 1 is fresh fragments (control group) and&#xD;
      group 2 is vitrified group. Ovarian tissues in group 2 will be vitrified or warmed with&#xD;
      medium and devices of Ova-kit type M (Kitazato, Japan).&#xD;
&#xD;
      Cortex fragments of each group will have:&#xD;
&#xD;
        -  Follicle survival evaluation by Neutral red staining&#xD;
&#xD;
        -  Histological evaluation by Hematoxylin and Eosin staining&#xD;
&#xD;
        -  Evaluation relative Growth Differentiation Factor 9 (GDF-9) and Caspase-3 gene&#xD;
           expression by real-time Polymerase chain reaction (PCR).&#xD;
&#xD;
      Comparison of data collected from 2 groups will be carried on to evaluate the effectiveness&#xD;
      of the technique before applying this technique for cancer patients in Vietnam.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Survivable follicle</measure>
    <time_frame>After 4 hours stained by Neutral red</time_frame>
    <description>Percentage of survivable follicles per counted follicles in one fragment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Healthy follicle by histological analysis</measure>
    <time_frame>Immediately after tissue stained by Hematoxylin and Eosin</time_frame>
    <description>Healthy follicles of primordial, primary, secondary follicles will be counted in one slide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative expression ratio ( R ) of genes in follicles</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Follicles in ovarian tissue will be collected, complementary deoxyribonucleic acid (cDNA) synthesis after messenger ribonucleic acid (mRNA) purification, relative quantification PCR for detecting gene expression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Ovarian Tissue Cryopreservation</condition>
  <condition>Vitrification</condition>
  <arm_group>
    <arm_group_label>Vitrified ovarian tissue</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>evaluation of the effectiveness of vitrification technique on ovarian tissue quality</intervention_name>
    <description>there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.</description>
    <arm_group_label>Vitrified ovarian tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ovaries from all less than 45 year-old breast cancer patients who undergo oophorectomy&#xD;
             by laparoscopy after treated with chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The volume of ovaries is less than 2/3 of normal 3cm (L) x 2.5cm (H) x 1.5cm (W)&#xD;
             ovary.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuong M Ho, MD, MCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lan N Nguyen, MSC</last_name>
    <phone>+84 906 969 280</phone>
    <email>nttlan@hyvonghospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dang Q Vinh, MD, MCE</last_name>
    <phone>+84908225481‬</phone>
    <email>bsvinh.dq@myduchospital.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>My Duc Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <contact>
      <last_name>Lan Nguyen, MSC</last_name>
      <phone>+84906969280</phone>
      <email>nttlan@hyvonghospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Vinh Dang, MD,MCE</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

